95 related articles for article (PubMed ID: 23904379)
1. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.
Rao YM; Shi HR; Ji M; Chen CH
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379
[TBL] [Abstract][Full Text] [Related]
2. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
[TBL] [Abstract][Full Text] [Related]
3. Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer.
Zhang Q; Guo F; Liu H; Hong L
Int Wound J; 2024 Apr; 21(4):e14569. PubMed ID: 38158767
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway.
Echevarría-Vargas IM; Valiyeva F; Vivas-Mejía PE
PLoS One; 2014; 9(5):e97094. PubMed ID: 24865582
[TBL] [Abstract][Full Text] [Related]
5. Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis.
Zhang XY; Zhu BC; He M; Dong SS
J Ovarian Res; 2024 May; 17(1):102. PubMed ID: 38745302
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract][Full Text] [Related]
7. NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines.
Ghini V; Sorbi F; Fambrini M; Magherini F
Cells; 2024 Apr; 13(8):. PubMed ID: 38667276
[TBL] [Abstract][Full Text] [Related]
8. Targeting SOD1 via RNAi with PEGylated graphene oxide nanoparticles in platinum-resistant ovarian cancer.
Szénási A; Sivasudhan E; Du H; Zhang P; Huang J; Zhang Z; Rocha S; Wang M
Cancer Gene Ther; 2023 Nov; 30(11):1554-1568. PubMed ID: 37582934
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the role of microRNA 374b in acquired cisplatin resistance in pancreatic cancer cells.
Schreiber R; Mezencev R; Matyunina LV; McDonald JF
Cancer Gene Ther; 2016 Aug; 23(8):241-5. PubMed ID: 27229158
[TBL] [Abstract][Full Text] [Related]
10. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1.
Cai Y; Li Y; Xu Y; Yang W; Huang M
FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
[TBL] [Abstract][Full Text] [Related]
11. Resistance Improvement and Sensitivity Enhancement of Cancer Therapy by a Novel Antitumor Candidate onto A2780 CP and A2780 S Cell Lines.
Mohammadi Hadloo S; Mohseni Kouchesfahani H; Khanlarkhani A; Saeidifar M
Rep Biochem Mol Biol; 2023 Oct; 12(3):374-385. PubMed ID: 38618266
[TBL] [Abstract][Full Text] [Related]
12. Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780.
Engelke LH; Hamacher A; Proksch P; Kassack MU
J Cancer; 2016; 7(4):353-63. PubMed ID: 26918049
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.
Zhao Z; Ji M; Wang Q; He N; Li Y
Mol Ther Nucleic Acids; 2019 Dec; 18():24-33. PubMed ID: 31479922
[TBL] [Abstract][Full Text] [Related]
14. Association between circadian gene
Xu H; Wang Z; Mo G; Chen H
Oncol Lett; 2018 Jun; 15(6):8945-8950. PubMed ID: 29844814
[TBL] [Abstract][Full Text] [Related]
15. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.
Geretto M; Pulliero A; Rosano C; Zhabayeva D; Bersimbaev R; Izzotti A
Am J Cancer Res; 2017; 7(6):1350-1371. PubMed ID: 28670496
[TBL] [Abstract][Full Text] [Related]
16. Peroxiredoxin-1 as a molecular chaperone that regulates glutathione S-transferase P1 activity and drives mutidrug resistance in ovarian cancer cells.
Fan C; Yuan S; Zhang Y; Nie Y; Xiang L; Luo T; Xi Q; Zhang Y; Gu Z; Wang P; Zhou H
Biochem Biophys Rep; 2024 Mar; 37():101639. PubMed ID: 38288281
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
Ma Y; Li X; Cheng S; Wei W; Li Y
Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
[TBL] [Abstract][Full Text] [Related]
18. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer.
Zheng H; Zhang L; Zhao Y; Yang D; Song F; Wen Y; Hao Q; Hu Z; Zhang W; Chen K
PLoS One; 2013; 8(11):e77853. PubMed ID: 24223734
[TBL] [Abstract][Full Text] [Related]
19. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
20. Overview of miR-106a Regulatory Roles: from Cancer to Aging.
Daneshpour M; Ghadimi-Daresajini A
Bioengineering (Basel); 2023 Jul; 10(8):. PubMed ID: 37627777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
